Published in J Biol Chem on July 04, 1997
Electrostatics of nanosystems: application to microtubules and the ribosome. Proc Natl Acad Sci U S A (2001) 42.14
Cancer drug resistance: an evolving paradigm. Nat Rev Cancer (2013) 6.77
Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov (2010) 4.66
Mechanisms of Taxol resistance related to microtubules. Oncogene (2003) 3.16
Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res (2011) 2.69
A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci U S A (2000) 2.20
The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel. Cancer Cell (2007) 2.05
Resistance to Taxol in lung cancer cells associated with increased microtubule dynamics. Proc Natl Acad Sci U S A (2001) 2.00
The binding conformation of Taxol in beta-tubulin: a model based on electron crystallographic density. Proc Natl Acad Sci U S A (2001) 1.80
FoxM1 mediates resistance to herceptin and paclitaxel. Cancer Res (2010) 1.78
Relating molecular flexibility to function: a case study of tubulin. Biophys J (2002) 1.62
A common pharmacophore for cytotoxic natural products that stabilize microtubules. Proc Natl Acad Sci U S A (1999) 1.49
Antisense oligonucleotides to class III beta-tubulin sensitize drug-resistant cells to Taxol. Br J Cancer (1999) 1.45
Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel. Proc Natl Acad Sci U S A (1998) 1.42
Evaluation of the tubulin-bound paclitaxel conformation: synthesis, biology, and SAR studies of C-4 to C-3' bridged paclitaxel analogues. J Med Chem (2007) 1.42
Functional genomic analysis of chromosomal aberrations in a compendium of 8000 cancer genomes. Genome Res (2012) 1.39
Class III beta-tubulin expression and in vitro resistance to microtubule targeting agents. Br J Cancer (2009) 1.32
Understanding tubulin-Taxol interactions: mutations that impart Taxol binding to yeast tubulin. Proc Natl Acad Sci U S A (2003) 1.30
Design, synthesis, and biological evaluation of new-generation taxoids. J Med Chem (2008) 1.29
The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase. Cancer Res (2005) 1.28
Mitotic kinesin inhibitors induce mitotic arrest and cell death in Taxol-resistant and -sensitive cancer cells. J Biol Chem (2005) 1.27
Microtubule disruption targets HIF-1alpha mRNA to cytoplasmic P-bodies for translational repression. J Cell Biol (2011) 1.26
Taxol allosterically alters the dynamics of the tubulin dimer and increases the flexibility of microtubules. Biophys J (2008) 1.24
EF24, a novel curcumin analog, disrupts the microtubule cytoskeleton and inhibits HIF-1. Cell Cycle (2008) 1.23
Epithelial ovarian cancer experimental models. Oncogene (2013) 1.23
Drug-resistant T-lymphoid tumors undergo apoptosis selectively in response to an antimicrotubule agent, EM011. Blood (2005) 1.19
Microtubule stabilizing agents as potential treatment for Alzheimer's disease and related neurodegenerative tauopathies. J Med Chem (2012) 1.17
Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells. J Transl Med (2008) 1.15
Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer. Br J Cancer (2010) 1.15
Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone. Breast Cancer Res (2010) 1.14
OxLDL-dependent activation of arginase II is dependent on the LOX-1 receptor and downstream RhoA signaling. Atherosclerosis (2010) 1.12
Modulation of paclitaxel resistance by annexin IV in human cancer cell lines. Br J Cancer (2000) 1.12
Targeting microtubules by natural agents for cancer therapy. Mol Cancer Ther (2014) 1.08
Mutations in topoisomerase I as a self-resistance mechanism coevolved with the production of the anticancer alkaloid camptothecin in plants. Proc Natl Acad Sci U S A (2008) 1.07
Hallmarks of molecular action of microtubule stabilizing agents: effects of epothilone B, ixabepilone, peloruside A, and laulimalide on microtubule conformation. J Biol Chem (2011) 1.07
Src family kinases and paclitaxel sensitivity. Cancer Biol Ther (2011) 1.05
Endometrial carcinoma: a review of chemotherapy, drug resistance, and the search for new agents. Oncologist (2010) 1.03
Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells. Breast Cancer Res (2009) 1.03
Txr1: a transcriptional regulator of thrombospondin-1 that modulates cellular sensitivity to taxanes. Genes Dev (2006) 1.02
Microtubule-stabilizing agents based on designed laulimalide analogues. Proc Natl Acad Sci U S A (2004) 1.01
Tumor interstitial fluid pressure as an early-response marker for anticancer therapeutics. Neoplasia (2009) 1.01
The roles of beta-tubulin mutations and isotype expression in acquired drug resistance. Cancer Inform (2007) 0.98
Recent advances in the chemistry and biology of new generation taxoids. J Nat Prod (2009) 0.98
The protein farnesyltransferase regulates HDAC6 activity in a microtubule-dependent manner. J Biol Chem (2009) 0.98
Beta class II tubulin predominates in normal and tumor breast tissues. Breast Cancer Res (2003) 0.97
New insights into mechanisms of resistance to microtubule inhibitors. Biochim Biophys Acta (2011) 0.96
p63 expression correlates with sensitivity to the Eg5 inhibitor ZD4877 in bladder cancer cells. Cancer Biol Ther (2012) 0.96
Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry. Invest New Drugs (2007) 0.94
TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: a non-randomized retrospective study. BMC Cancer (2008) 0.94
Eribulin -- a review of preclinical and clinical studies. Crit Rev Oncol Hematol (2011) 0.94
Paclitaxel-induced microtubule stabilization causes mitotic block and apoptotic-like cell death in a paclitaxel-sensitive strain of Saccharomyces cerevisiae. Yeast (2005) 0.93
The paclitaxel site in tubulin probed by site-directed mutagenesis of Saccharomyces cerevisiae beta-tubulin. FEBS Lett (2008) 0.91
MDR 1 activation is the predominant resistance mechanism selected by vinblastine in MES-SA cells. Br J Cancer (2000) 0.91
Thymidine Phosphorylase/β-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel. BMC Cancer (2011) 0.91
Farnesyltransferase inhibitors reverse taxane resistance. Cancer Res (2006) 0.90
Mutations in the β-tubulin binding site for peloruside A confer resistance by targeting a cleft significant in side chain binding. Cell Cycle (2011) 0.90
Microtubule-disrupting chemotherapeutics result in enhanced proteasome-mediated degradation and disappearance of tubulin in neural cells. Cancer Res (2010) 0.89
Synthesis and biological evaluation of (-)-dictyostatin and stereoisomers. Tetrahedron (2007) 0.89
Clinical trials and progress with paclitaxel in ovarian cancer. Int J Womens Health (2010) 0.89
ERG induces taxane resistance in castration-resistant prostate cancer. Nat Commun (2014) 0.89
FOXM1 mediates resistance to docetaxel in gastric cancer via up-regulating Stathmin. J Cell Mol Med (2014) 0.89
A simplified synthesis of novel dictyostatin analogues with in vitro activity against epothilone B-resistant cells and antiangiogenic activity in zebrafish embryos. Mol Cancer Ther (2011) 0.88
A tubulin binding peptide targets glioma cells disrupting their microtubules, blocking migration, and inducing apoptosis. Mol Ther (2012) 0.88
Taxotere resistance in SUIT Taxotere resistance in pancreatic carcinoma cell line SUIT 2 and its sublines. World J Gastroenterol (2001) 0.88
Mechanisms of resistance to cabazitaxel. Mol Cancer Ther (2014) 0.87
Drug resistance to paclitaxel is not only associated with ABCB1 mRNA expression but also with drug accumulation in intracellular compartments in human lung cancer cell lines. Int J Oncol (2011) 0.87
Secretory leukocyte protease inhibitor antagonizes paclitaxel in ovarian cancer cells. Clin Cancer Res (2010) 0.87
Enhancing effectiveness of the MDR-sensitive compound T138067 using advanced treatment with negative modulators of the drug-resistant protein survivin. Am J Transl Res (2009) 0.87
Resistance to microtubule-stabilizing drugs involves two events: beta-tubulin mutation in one allele followed by loss of the second allele. Cell Cycle (2005) 0.87
Specific β-tubulin isotypes can functionally enhance or diminish epothilone B sensitivity in non-small cell lung cancer cells. PLoS One (2011) 0.87
Drug discovery targeting cell division proteins, microtubules and FtsZ. Bioorg Med Chem (2014) 0.86
Taxol-resistance-associated gene-3 (TRAG-3/CSAG2) expression is predictive for clinical outcome in ovarian carcinoma patients. Virchows Arch (2007) 0.86
Higher sensitivity to patupilone versus paclitaxel chemotherapy in primary uterine serous papillary carcinoma cell lines with high versus low HER-2/neu expression in vitro. Gynecol Oncol (2010) 0.86
Synthesis and Biological Evaluation of Novel 3'-Difluorovinyl Taxoids. J Fluor Chem (2012) 0.86
Modulation of endogenous beta-tubulin isotype expression as a result of human beta(III)cDNA transfection into prostate carcinoma cells. Br J Cancer (2001) 0.85
Altered TUBB3 expression contributes to the epothilone response of mitotic cells. Br J Cancer (2013) 0.85
Can the status of the breast and ovarian cancer susceptibility gene 1 product (BRCA1) predict response to taxane-based cancer therapy? Anticancer Agents Med Chem (2009) 0.84
No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin. BMC Cancer (2005) 0.84
Peloruside- and laulimalide-resistant human ovarian carcinoma cells have βI-tubulin mutations and altered expression of βII- and βIII-tubulin isotypes. Mol Cancer Ther (2011) 0.84
Drug resistance associated with loss of p53 involves extensive alterations in microtubule composition and dynamics. Br J Cancer (2003) 0.83
Acetylated tubulin (AT) as a prognostic marker in squamous cell carcinoma of the head and neck. Head Neck Pathol (2013) 0.82
Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer. Biomed Res Int (2015) 0.82
Inhibition of SIRT2 potentiates the anti-motility activity of taxanes: implications for antineoplastic combination therapies. Neoplasia (2012) 0.82
Understanding the basis of drug resistance of the mutants of αβ-tubulin dimer via molecular dynamics simulations. PLoS One (2012) 0.81
Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trial. PLoS One (2013) 0.81
Design and synthesis of C6-C8 bridged epothilone A. Org Lett (2008) 0.81
Response to microtubule-interacting agents in primary epithelial ovarian cancer cells. Cancer Cell Int (2013) 0.81
Comparison of Epothilone and Taxol Binding in Yeast Tubulin using Molecular Modeling. Avicenna J Med Biotechnol (2011) 0.80
Bisphosphorylated PEA-15 sensitizes ovarian cancer cells to paclitaxel by impairing the microtubule-destabilizing effect of SCLIP. Mol Cancer Ther (2013) 0.80
Conformation-activity relationships of polyketide natural products. Nat Prod Rep (2015) 0.80
Nanoparticle-mediated drug delivery for treating melanoma. Nanomedicine (Lond) (2015) 0.79
Synergistic suppression of noscapine and conventional chemotherapeutics on human glioblastoma cell growth. Acta Pharmacol Sin (2013) 0.79
Differentiating between models of epothilone binding to microtubules using tubulin mutagenesis, cytotoxicity, and molecular modeling. ChemMedChem (2012) 0.79
Subcellular distribution of epothilones in human tumor cells. Proc Natl Acad Sci U S A (2001) 0.79
Investigation of antitumor effects of synthetic epothilone analogs in human myeloma models in vitro and in vivo. Proc Natl Acad Sci U S A (2005) 0.79
Improved biochemical strategies for targeted delivery of taxoids. Bioorg Med Chem (2007) 0.79
Human amniotic mesenchymal stromal cells (hAMSCs) as potential vehicles for drug delivery in cancer therapy: an in vitro study. Stem Cell Res Ther (2015) 0.79
Polyketide-nonribosomal peptide epothilone antitumor agents: the EpoA, B, C subunits. J Ind Microbiol Biotechnol (2003) 0.79
p38 MAPK-induced MDM2 degradation confers paclitaxel resistance through p53-mediated regulation of EGFR in human lung cancer cells. Oncotarget (2016) 0.79
A novel microtubule inhibitor 4SC-207 with anti-proliferative activity in taxane-resistant cells. PLoS One (2013) 0.78
Evidence based medicine: what it is and what it isn't. BMJ (1996) 66.70
Inpatient general medicine is evidence based. A-Team, Nuffield Department of Clinical Medicine. Lancet (1995) 24.14
Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med (1991) 18.33
The Burlington randomized trial of the nurse practitioner. N Engl J Med (1974) 17.02
Bias in analytic research. J Chronic Dis (1979) 16.40
A controlled trial of teaching critical appraisal of the clinical literature to medical students. JAMA (1987) 14.20
The number needed to treat: a clinically useful measure of treatment effect. BMJ (1995) 13.89
An assessment of clinically useful measures of the consequences of treatment. N Engl J Med (1988) 13.02
An information-intensive approach to the molecular pharmacology of cancer. Science (1997) 11.43
Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med (1998) 11.27
Increased absenteeism from work after detection and labeling of hypertensive patients. N Engl J Med (1978) 9.29
Controversy in the detection of disease. Lancet (1975) 7.85
How to keep up with the medical literature: V. Access by personal computer to the medical literature. Ann Intern Med (1986) 7.36
Controversy in counting and attributing events in clinical trials. N Engl J Med (1979) 7.25
Randomised clinical trial of strategies for improving medication compliance in primary hypertension. Lancet (1975) 7.22
Users' guides to the medical literature. I. How to get started. The Evidence-Based Medicine Working Group. JAMA (1993) 6.83
A utility maximization model for evaluation of health care programs. Health Serv Res (1972) 6.67
Users' guides to the medical literature. IX. A method for grading health care recommendations. Evidence-Based Medicine Working Group. JAMA (1995) 5.28
Problems in the handling of clinical and research evidence by medical practitioners. Arch Intern Med (1983) 5.16
A randomized trial of continuing medical education. N Engl J Med (1982) 4.95
Improvement of medication compliance in uncontrolled hypertension. Lancet (1976) 4.84
The Burlington randomized trial of the nurse practitioner: health outcomes of patients. Ann Intern Med (1974) 4.37
The utility of different health states as perceived by the general public. J Chronic Dis (1978) 3.65
An empirical demonstration of Berkson's bias. J Chronic Dis (1978) 3.48
Can simple clinical measurements detect patient noncompliance? Hypertension (1981) 3.29
Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation (1996) 3.23
Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest (1986) 3.16
p53 is associated with cellular microtubules and is transported to the nucleus by dynein. Nat Cell Biol (2000) 3.05
Does a mailed continuing education program improve physician performance? Results of a randomized trial in antihypertensive care. JAMA (1986) 3.04
Choosing the best research design for each question. BMJ (1998) 3.03
Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med (1986) 3.00
The measurement iterative loop: a framework for the critical appraisal of need, benefits and costs of health interventions. J Chronic Dis (1985) 2.96
How to keep up with the medical literature: I. Why try to keep up and how to get started. Ann Intern Med (1986) 2.94
Quality-of-care appraisal in primary care: a quantitative method. Ann Intern Med (1975) 2.87
Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest (1992) 2.81
Centrosome amplification and instability occurs exclusively in aneuploid, but not in diploid colorectal cancer cell lines, and correlates with numerical chromosomal aberrations. Genes Chromosomes Cancer (2000) 2.73
Methodologic guidelines for systematic reviews of randomized control trials in health care from the Potsdam Consultation on Meta-Analysis. J Clin Epidemiol (1995) 2.73
Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res (1999) 2.70
Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol (1996) 2.67
The development and application of indices of health: general methods and a summary of results. Am J Public Health (1977) 2.53
Clinical recommendations using levels of evidence for antithrombotic agents. Chest (1995) 2.52
Using research findings in clinical practice. BMJ (1998) 2.40
The rational clinical examination. Does this patient have splenomegaly? JAMA (1993) 2.38
The rational clinical examination. Does this patient have a clinically important carotid bruit? JAMA (1993) 2.38
Hypertension in a family practice. Can Med Assoc J (1977) 2.36
Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br J Cancer (2003) 2.33
Role of CYP2E1 in the hepatotoxicity of acetaminophen. J Biol Chem (1996) 2.25
A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci U S A (2000) 2.20
Rules of evidence and clinical recommendations for the management of patients. Can J Cardiol (1993) 2.11
When was a "negative" clinical trial big enough? How many patients you needed depends on what you found. Arch Intern Med (1985) 2.11
Transferring evidence from research into practice: 1. The role of clinical care research evidence in clinical decisions. ACP J Club (1996) 2.10
Cost effectiveness of clinical diagnosis, venography, and noninvasive testing in patients with symptomatic deep-vein thrombosis. N Engl J Med (1981) 2.04
Guidelines for managing raised blood pressure. BMJ (1996) 2.03
p53 inhibits hypoxia-inducible factor-stimulated transcription. J Biol Chem (1998) 1.94
Microtubule-interfering agents activate c-Jun N-terminal kinase/stress-activated protein kinase through both Ras and apoptosis signal-regulating kinase pathways. J Biol Chem (1998) 1.93
Cardiovascular diseases. Lancet (1974) 1.85
Fenoterol and fatal asthma. Lancet (1990) 1.77
Labelling in hypertension: a review of the behavioural and psychological consequences. J Chronic Dis (1984) 1.75
How to keep up with the medical literature: IV. Using the literature to solve clinical problems. Ann Intern Med (1986) 1.75
Cochrane Collaboration. BMJ (1994) 1.74
Educational package on hypertension for primary care physicians. Can Med Assoc J (1984) 1.73
Tubulin subunit carboxyl termini determine polymerization efficiency. J Biol Chem (1985) 1.73
Odds ratios should be avoided when events are common. BMJ (1998) 1.71
Deletions into an NH2-terminal hydrophobic domain result in secretion of rotavirus VP7, a resident endoplasmic reticulum membrane glycoprotein. J Cell Biol (1985) 1.70
Molecular effects of paclitaxel: myths and reality (a critical review). Int J Cancer (1999) 1.70
Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol (2009) 1.67
Clinical diagnosis and the clinical laboratory. Clin Invest Med (1978) 1.67
Combined use of leg scanning and impedance plethysmography in suspected venous thrombosis. An alternative to venography. N Engl J Med (1977) 1.66
Physics-based protein-structure prediction using a hierarchical protocol based on the UNRES force field: assessment in two blind tests. Proc Natl Acad Sci U S A (2005) 1.65
Protection against acetaminophen toxicity in CYP1A2 and CYP2E1 double-null mice. Toxicol Appl Pharmacol (1998) 1.63
Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res (1999) 1.62
Search for supersymmetry using final states with one lepton, jets, and missing transverse momentum with the ATLAS detector in √s=7 TeV pp collisions. Phys Rev Lett (2011) 1.60
Topology of the non-structural rotavirus receptor glycoprotein NS28 in the rough endoplasmic reticulum. EMBO J (1989) 1.60
Understanding clinical trials. BMJ (1994) 1.59
How to keep up with the medical literature: II. Deciding which journals to read regularly. Ann Intern Med (1986) 1.57
Transcription activation via enhanced preinitiation complex assembly in a human cell-free system lacking TAFIIs. Mol Cell (1998) 1.56
Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death. Cancer Res (1997) 1.56
Tubulin, hybrid dimers, and tubulin S. Stepwise charge reduction and polymerization. J Biol Chem (1985) 1.54
Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. J Clin Endocrinol Metab (2001) 1.54
On the need for evidence-based medicine. Health Econ (1996) 1.53
Evaluation of neonatal-intensive-care program. N Engl J Med (1981) 1.52
Cancer risk in ulcerative colitis: scientific requirements for the study of prognosis. Gastroenterology (1980) 1.50
The fall of "clinical research" and the rise of "clinical-practice research". Clin Invest Med (2000) 1.50
The science of the art of the clinical examination. JAMA (1992) 1.48
Self-recording of blood pressure in the management of hypertension. Can Med Assoc J (1978) 1.46
The usefulness of laboratory tests in health-screening programs. Clin Chem (1973) 1.45
Applying the results of trials and systematic reviews to individual patients. ACP J Club (1998) 1.45
Concordance for coronary risk factors among spouses. Circulation (1975) 1.44